Price Target Update on Shire plc (NASDAQ:SHPG)

Shire plc (NASDAQ:SHPG) : The most positive equity analysts on Shire plc (NASDAQ:SHPG) expects the shares to touch $325, whereas, the least positive believes that the stock will trade at $174 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $248.92 with an expected fluctuation of $40.26 from the mean.

Other Equity analysts have also commented on the company shares. Morgan Stanley assumes their rating on the shares of Shire plc (NASDAQ:SHPG). The current rating of the shares is Overweight. The rating by the firm was issued on June 3, 2016.

Shire plc (NASDAQ:SHPG): stock turned positive on Thursday. Though the stock opened at $182.28, the bulls momentum made the stock top out at $182.405 level for the day. The stock recorded a low of $178.47 and closed the trading day at $180.29, in the green by 2.80%. The total traded volume for the day was 3,494,292. The stock had closed at $175.38 in the previous days trading.

The company shares have dropped -30.42% from its 1 Year high price. On Jul 29, 2015, the shares registered one year high at $270.63 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $180.69 and the 200 Day Moving Average price is recorded at $177.51.

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.